PHY906

DRUG3 trials

Sponsors

PhytoCeutica, Yale University

Conditions

Colorectal NeoplasmsDiarrheaHepatocellular CarcinomaLiver CancerPancreatic Cancer

Phase 1

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

TerminatedNCT00036517

PhytoCeuticaColorectal Neoplasms, Diarrhea

Start: 2002-02-28End: 2003-03-31Target: 30Updated: 2005-06-24

Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma

CompletedNCT00076609

PhytoCeuticaHepatocellular Carcinoma, Liver Cancer

Start: 2003-10-31Target: 31Updated: 2007-03-28

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

CompletedNCT00411762

Yale UniversityPancreatic Cancer

Start: 2006-12-31End: 2009-12-31Updated: 2015-03-27

Related Papers

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma

The Oncologist2020-11-0341 citations